drugset
drugset / Trial / NCT07552077

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

NCT07552077 ↗

Phase 2 Recruiting 15 enrolled Palvella Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas

Timeline

Start
2026-04
Primary completion
2027-08
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 3.9 % Topical

Indications

angiokeratoma